Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TransCon TLR 7/8 agonist - Ascendis Pharma

Next Previous
X
Search
Drug Profile

TransCon TLR 7/8 agonist - Ascendis Pharma

Alternative Names: TransCon TLR7/8 Agonist; TransCon Toll-like Receptor 7/8 Agonist

Latest Information Update: 27 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascendis Pharma
  • Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Quinolones; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Squamous cell cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 29 Sep 2023 Phase-II clinical trials in Squamous cell cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (Intratumoural) (NCT05980598)
  • 19 May 2023 Ascendis Pharma has multiple patents granted and pending for TransCon TLR7/8 in several countries
  • 27 Apr 2023 Ascendis Pharma plans a phase II Believe-IT-201 trial of TransCon IL-2 β/γ and TransCon TLR7/8 (Combination therapy) in the second quarter of 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top